Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer

Summary

This phase II trial is studying blood and tumor tissue from patients with advanced non-small cell lung cancer who are treated with nivolumab to better understand how nivolumab works. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread by turning on the immune system (T cells). We want to study the effects of nivolumab on the immune system (T cells) by collecting blood samples and samples from patients' tumors.

Timeline

Start

2017-07-21

Primary completion

2019-03-09

Completion

2019-03-09

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Drugs

Indications